The efficacy, safety, and pharmacokinetics/pharmacodynamics of telitacicept following efgartigimod in generalized myasthenia gravis: protocol of a randomized controlled trial
The study has been approved by the Ethics Committee in Clinical Research of the First Affiliated Hospital of Wenzhou Medical University. Results of the study will be disseminated to the relevant scientific, clinical and patient communities on trial closure. Trial registration number: The study was registered at ClinicalTrials.gov (NCT06827587).
Authors
- Feiteng Qi (ORCID: https://orcid.org/0009-0007-4362-9086)
- Qiaoyi Zhang
- Bingbing Wan
- Yan Deng (ORCID: https://orcid.org/0000-0002-3185-3810)
- Yiyun Weng (ORCID: https://orcid.org/0000-0002-1407-4276)
- Shengli Pan (ORCID: https://orcid.org/0000-0002-1904-6557)
- Xiang Li (ORCID: https://orcid.org/0000-0002-0016-6233)
- Wenyu Li (ORCID: https://orcid.org/0000-0003-0218-589X)
- Yu Zhang (ORCID: https://orcid.org/0000-0003-3474-422X)
- Li Jia (ORCID: https://orcid.org/0000-0002-1979-5128)
- Yuan Zhang (ORCID: https://orcid.org/0009-0003-5998-1544)
- Shuya Yang
- Xu Zhang (ORCID: https://orcid.org/0009-0004-4086-9541)
- Zheyu Fang
- Xi Long Qu
- Yiqi Wang
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- Sir Run Run Shaw Hospital (CN)
- Ningbo Medical Center Lihuili Hospital (CN)
- Zhejiang Provincial People's Hospital (CN)
- Second Affiliated Hospital of Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-10-22
- DOI
- https://doi.org/10.3389/fimmu.2025.1604786
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Wenzhou Medical University